Kanvas Biosciences secures $48M Series A funding led by DCVC and Lions Capital to advance immunotherapy treatments for cancer patients.
Amount Raised
$48 Million
Round Type
Series A
Monmouth JunctionBiotechnologyHealthcareInvestors
Description
Kanvas Biosciences has raised $48 million in a Series A funding round to advance its lead immuno-oncology drug, KAN-001, aimed at improving treatment efficacy for cancer patients. The round includes investors like DCVC, Lions Capital LLC, and Gates Foundation. This funding will support clinical trials and enhance commercial partnerships leveraging their spatial imaging and manufacturing platform. Kanvas has now raised a total of $78 million in funding.
Quick answer
Kanvas Biosciences raised $48 Million in a Series A round, dated May 6, 2026. Investors: Germin8, Gates Foundation, Athos KG, Ki Tua Fund, Pangaea Ventures, Dcvc and Lions Capital LLC. Kanvas Biosciences is based in Monmouth Junction, New Jersey, United States.
- How much did Kanvas Biosciences raise?
- Kanvas Biosciences raised $48 Million in a Series A round on May 6, 2026.
- Who invested in Kanvas Biosciences?
- Germin8, Gates Foundation, Athos KG, Ki Tua Fund, Pangaea Ventures, Dcvc and Lions Capital LLC are named as investors in this round.
- What does Kanvas Biosciences do?
- Kanvas Biosciences is building the world's first microbiome drug screening and drug discovery platform to accelerate live biotherapeutic product (LBP) development.
- Where is Kanvas Biosciences based and how big is it?
- Kanvas Biosciences is based in Monmouth Junction, New Jersey, United States. Fundz records about 42 employees.
- Who are the decision-makers at Kanvas Biosciences?
- Fundz holds 1 contact at Kanvas Biosciences. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Biotechnology around the same time
Companies in the same sectors as Kanvas Biosciences that raised within 45 days of this round, from Fundz verified event records.
- Pneuma Respiratory raised $3.6M on June 18, 2026.
- RedHill Biopharma Ltd raised $6M (Post-IPO Equity) on June 18, 2026.
- CEL-SCI Corporation raised $2.5M (Post-IPO Equity) on June 14, 2026.
- NeOnc Technologies raised $15M on June 10, 2026.
- Aspira Women’s Health raised $1.5M on June 5, 2026.
- Tempest Therapeutics raised $4.1M on May 29, 2026.
Who to call at Kanvas Biosciences, and when
A new round usually means Kanvas Biosciences is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Kanvas Biosciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Kanvas Biosciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Kanvas Biosciences. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Kanvas Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansKanvas Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.